Protalix BioTherapeutics enters fill/finish deal with Chiesi for PRX-102 launch

Protalix BioTherapeutics, Inc.

Agreement with Chiesi for commercial fill/finish services for PRX-102 (Fabry disease candidate).
Protalix to supply drug substance; Chiesi will provide fill/finish services for global launch.
Term through Dec 31, 2025, renewable for 7 years by mutual agreement.
Letter Agreement modifies License Agreements to establish Chiesi as supplier and potential alternate source.
Agreement supports anticipated launch; no financial terms disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.